Literature DB >> 9106447

Quantitative cytochemistry of cytochrome oxidase and cellular morphometry of the human inferior colliculus in control and Alzheimer's patients.

F Gonzalez-Lima1, J Valla, S Matos-Collazo.   

Abstract

Quantitative cytochemistry of cytochrome oxidase (C.O.) was implemented in human brains to measure C.O. activity in the 3 main divisions of the inferior colliculus (IC): central (ICC), dorsal (ICD), and external (ICE). Units of C.O. activity (micromol/min/g tissue wet weight) were quantified in cellular compartments (overall average, neuropil, perikaryon, and dendrites) at the light microscope level using microdensitometry calibrated with C.O. activity standards measured spectrophotometrically. In a non-AD (Alzheimer's disease) control group (mean age = 79.6 +/- 3.1 years, postmortem time = 6.9 +/- 1.6 h), the ICC and ICD demonstrated higher (p < 0.008) overall average activities (mean = 183.40 +/- 18.7 and 184.98 +/- 45.1 units, respectively) relative to the ICE (56.46 +/- 15.9 units). Comparison of cellular morphometry (soma and nucleus area, perimeter, and diameter) revealed that the ICC contained cells of significantly larger soma size than in both the ICD and ICE (p < 0.002). The distribution of soma diameters in the ICC of controls showed a clear bimodality, enabling the typing of the cells into larger and smaller than average soma diameter. Brains from patients with Alzheimer's disease (AD; mean age = 78.3 +/- 2.9 years, postmortem time = 6.5 +/- 1.3 h) were compared with the non-AD controls. Significant group differences were found only in the large cells of the ICC. The AD large cells showed a decrement in C.O. activity relative to the corresponding controls in overall average activity (p < 0.032) and in peak activity of neuropil near the soma (p < 0.012). These findings provide the first quantitative cytochemical data of C.O. activity in humans. They also suggest that cellular alterations in C.O. metabolism in AD affect predominantly specific groups of larger projection neurons while neighboring neurons are spared.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106447     DOI: 10.1016/s0006-8993(96)01464-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease.

Authors:  M Y Aksenov; H M Tucker; P Nair; M V Aksenova; D A Butterfield; S Estus; W R Markesbery
Journal:  Neurochem Res       Date:  1999-06       Impact factor: 3.996

Review 2.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 3.  Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease.

Authors:  M Isabel G Lopez Sanchez; Peter van Wijngaarden; Ian A Trounce
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

Review 4.  Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.

Authors:  Gunter P Eckert; Kathrin Renner; Schamim H Eckert; Janett Eckmann; Stephanie Hagl; Reham M Abdel-Kader; Christopher Kurz; Kristina Leuner; Walter E Muller
Journal:  Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.590

5.  Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration.

Authors:  J Valla; J D Berndt; F Gonzalez-Lima
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

6.  Astrocytic gap junctional communication is reduced in amyloid-β-treated cultured astrocytes, but not in Alzheimer's disease transgenic mice.

Authors:  Nancy F Cruz; Kelly K Ball; Gerald A Dienel
Journal:  ASN Neuro       Date:  2010-08-17       Impact factor: 4.146

Review 7.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

8.  Methylene blue prevents neurodegeneration caused by rotenone in the retina.

Authors:  Xian Zhang; Julio C Rojas; F Gonzalez-Lima
Journal:  Neurotox Res       Date:  2006-01       Impact factor: 3.911

9.  Trafficking of glucose, lactate, and amyloid-beta from the inferior colliculus through perivascular routes.

Authors:  Kelly K Ball; Nancy F Cruz; Robert E Mrak; Gerald A Dienel
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-30       Impact factor: 6.200

Review 10.  Methylene blue and its analogues as antidepressant compounds.

Authors:  Anzelle Delport; Brian H Harvey; Anél Petzer; Jacobus P Petzer
Journal:  Metab Brain Dis       Date:  2017-07-31       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.